<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Patients with <z:hpo ids='HP_0002863'>myelodysplastic syndromes</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>) show a decrease in the number and function of natural killer (NK) cells, including lymphokine activated killer (LAK) cell activity </plain></SENT>
<SENT sid="1" pm="."><plain>Interleukin-2 (IL-2) stimulates the proliferation and activity of these lymphocytes </plain></SENT>
<SENT sid="2" pm="."><plain>Anecdotal clinical experience has shown haematological and cytogenetic improvement in <z:hpo ids='HP_0002863'>myelodysplasia</z:hpo> by low-dose IL-2 treatment </plain></SENT>
<SENT sid="3" pm="."><plain>A total of 10 patients with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> were treated with 1 million units of IL-2 subcutaneously daily for 12 weeks </plain></SENT>
<SENT sid="4" pm="."><plain>Even though improvement in CD16+/CD56+ cell numbers was seen in a majority of the patients, the haematological status and transfusion requirements remained unchanged </plain></SENT>
<SENT sid="5" pm="."><plain>There was minimal toxicity from this therapy </plain></SENT>
</text></document>